IMMUTEP LIMITED

0.60%

41.8¢

Market Cap $604.2M

Healthcare Biotechnology

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Latest Threads

Tag

Subject

IMM

IMM Chart

11:02

34K

11:02

Last post ahjay

34K

IMM

Media

9 10 11

20/01/26

656

305K

20/01/26

Last post simons77

656

305K

IMM

IMM 2026

16/01/26

14K

16/01/26

Last post SouthernAccent

14K

IMM

Ann: TACTI-004 phase III trial enrolment continues at robust pace

01/01/26

9.6K

01/01/26

Last post GreenWave

9.6K

IMM

Ann: Change in substantial holding

01/01/26

2.6K

01/01/26

Last post ahjay

2.6K

IMM

Ann: Positive Update on IMP761 Phase 1

28/12/25

13K

28/12/25

Last post ahjay

13K

IMM

Ann: Immutep enters into Strategic Collaboration with Dr. Reddy's

22/12/25

38K

22/12/25

Last post Glyderattack

38K

IMM

Ann: New data presentation from AIPAC-003 Phase II for SABCS

08/12/25

11K

08/12/25

Last post bioqld

11K

See All Discussions

Timeline

Change in substantial holding
31 Dec 08:27	Share

Positive Update on IMP761 Phase 1
22 Dec 08:25	Share

TACTI-004 phase III trial enrolment continues at robust pace
16 Dec 08:34	Share

Immutep enters into Strategic Collaboration with Dr. Reddy's
08 Dec 18:24	Share

Change of Director's Interest Notice - R Howard
05 Dec 19:34	Share

Change of Director's Interest Notice - P Meyers
05 Dec 19:28	Share

Change of Director's Interest Notice - L Boyce
05 Dec 19:27	Share

Application for quotation of securities - IMM
05 Dec 09:56	Share

Notification regarding unquoted securities - IMM
02 Dec 11:56	Share

New data presentation from AIPAC-003 Phase II for SABCS
02 Dec 09:29	Share

Results of Meeting
27 Nov 13:13	Share

Immutep AGM 2025 - Chairman's Address
27 Nov 10:51	Share

Immutep AGM 2025 - CEO's Presentation
27 Nov 10:47	Share

EFTISARC-NEO Phase II results presented at CTOS 2025
13 Nov 08:18	Share

Immutep Receives A$4.6 million French R&D Tax Incentive
03 Nov 09:28	Share

Immutep Quarterly Activities Report and Appendix 4C
29 Oct 08:22	Share

Annual Report filed on Form 20-F
27 Oct 08:15	Share

Notice of Annual General Meeting/Proxy Form
24 Oct 08:31	Share

Appendix 4G and Corporate Governance Statement
24 Oct 08:31	Share

Annual Report to shareholders
24 Oct 08:31	Share

Improved ORR in First Line NSCLC - presented at ESMO 2025
20 Oct 08:17	Share

Primary Endpoint Met in STS Trial - presented at ESMO 2025
20 Oct 08:17	Share

2025 Annual General Meeting and Key Dates
15 Oct 08:32	Share

Notification regarding unquoted securities - IMM
13 Oct 20:20	Share

Successful Completion of FDA Project Optimus Requirements
13 Oct 08:25	Share

TACTI-004 (KEYNOTE-F91) Phase 3 update in First Line NSCLC
09 Oct 08:35	Share

Change of Director's Interest Notice - P Meyers
08 Oct 10:03	Share

Change of Director's Interest Notice - F Triebel
08 Oct 10:01	Share

Change of Director's Interest Notice - M Voigt
08 Oct 10:00	Share

Application for quotation of securities - IMM
01 Oct 14:58	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 41.8¢		Change 0.003(0.60%)		Mkt cap ! $604.2M

Open	High	Low	Volume
42.0¢	42.5¢	41.5¢	596.7K

Buyers (Bids)

Vol.	Price($)
123999	41.5¢

Sellers (Offers)

Price($)	Vol.
42.0¢	19160

Last trade - 10.39am 21/01/2026 (20 minute delay)

IMM (ASX) Chart

IMMUTEP LIMITED

Latest Threads

Timeline

Featured News

Latest Videos

Immutep (ASX:IMM) enrols 50pc of patients for TACTI-003 trial

04 Jan 2023 08:19 (AEDT)

Latest Articles

Immutep notches upward on first lung cancer patient dosing

Immutep Ltd has dosed the first patient of its Phase 3 TACTI-004 non-small cell lung cancer trial in its final stage of clinical study.

Immutep dips as safety test for flagship drug IMP761 shows no adverse effects

Immutep has reported a small-scale conceptual safety test among 5 patients using flagship drug IMP761 has seen no adverse effects.

Immutep snaffles A$3.6M from French government for R&D

Immutep Ltd has received a R&D award of around A$3.6 million to develop two of its immunotherapy candidates

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News